Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Aβ deposition, in an AβPP/PS double transgenic mouse model of Alzheimer's disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
To determine the role of apolipoprotein E (apoE) in the deposition of different forms of Alzheimer amyloid deposit, we studied mice expressing both mutant human amyloid beta-protein precursor (AbetaPP) and presenilin 1 (PS1) that, in addition, were either normal or knocked-out for apoE. By 7 months of age, extensive deposits of amorphous amyloid beta (Abeta) had developed equally in both lines, indicating that, when present in high amounts, Abeta alone is sufficient for such deposition to occur. In contrast, filamentous, thioflavine S-positive amyloid deposition in AbetaPP/PS mice was catalyzed at least 3000 fold by apoE. Electron micrographs further illustrated the filamentous nature of Abeta deposits in mice expressing apoE. These and other behavior data indicate that the primary function of apoE in Alzheimer's disease is to promote the polymerization of Abeta into mature, beta pleated sheet filaments, a process that is necessary for inducing cognitive decline. Thus, preventing apoE from binding to Abeta may prove to be an effective means of therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 1×
“sembling that of end-stage human AD [3,5,9,15].”
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 2×
“Increases in both A β and apoE expression promote A β deposition in a dose dependent manner [1,6,7,10].”
Self-citationLack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Self-citationApolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802 · cited 1×
“The second protein is apolipoprotein E (apoE) which, when produced from the ε 4 allele, is the strongest known risk factor for developing sporadic AD besides age itself [16,17].”
Nilsson, L. N. G., Bales, K. R., DiCarlo, G., Gordon, M. N., Morgan, D., Paul, S. M., & Potter, H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01444.2001 · Cited by 137 · cited 3×
“In vitro [12] and in vivo [14] studies show that both of the major pathogenic chaperones found in amyloid β plaques, apoE and ACT, promote Aβ filament formation, with apoE showing the higher catalytic activity.”
InfluentialSelf-citation
Cited by
Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E
Fan, J., Donkin, J., & Wellington, C. (2009) · BioFactors · doi:10.1002/biof.37 · Cited by 97
Why lipids are important for Alzheimer disease?
Hirsch-Reinshagen, V., Burgess, B. L., & Wellington, C. L. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0012-2 · Cited by 86
Hirsch-Reinshagen, V., & Wellington, C. L. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32813aeabf · Cited by 61
Thal, D. R., Capetillo-Zarate, E., Schultz, C., Rüb, U., Saido, T. C., Yamaguchi, H., Haass, C., Griffin, W. S. T., Del Tredici, K., Braak, H., et al. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1053-1 · Cited by 50
Metadata
- Authors
- Costa, D. A., Nilsson, L. N. G., Bales, K. R., Paul, S. M., & Potter, H.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2004-10-20
- Volume
- 6
- Issue
- 5
- Pages
- 509-514
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1804478794
- Cited by
- 14
- References
- 5
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.